Related Experiment Video

Updated: Apr 17, 2026

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

7.6K

Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules

Cláudia M Deus, Gabriela L Santos, Rute Loureiro

  • 1CNC - Center for Neuroscience and Cell Biology, Largo Marques de Pombal, University of Coimbra, 3004-517 Coimbra, Portugal. pauloliv@ci.uc.pt.

Current Medicinal Chemistry
|February 11, 2015
PubMed

Insights

Mitochondria are key to cell life and death, and their altered metabolism drives cancer. New drugs targeting cancer cell mitochondria show promise, but delivery remains a challenge.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Mitochondria are crucial for cellular metabolism, cell death, and redox regulation.
  • Mitochondrial metabolic alterations are linked to various diseases, notably cancer, affecting tumor development.
  • Altered metabolic profiles in cancer cells present a promising target for novel anti-cancer therapies.

Purpose of the Study:

  • To review molecules targeting mitochondria in cancer cells currently in development.
  • To discuss strategies for improving the delivery of therapeutic agents into mitochondria.
  • To evaluate the advantages and disadvantages of different mitochondrial targeting strategies for cancer treatment.

Main Methods:

  • Literature review of molecules and strategies targeting mitochondria in cancer.
  • Analysis of challenges in delivering compounds across mitochondrial membranes.
  • Examination of drug delivery systems, including delocalized lipophilic cations and peptides.

Main Results:

  • Several molecules targeting cancer cell mitochondria are in various developmental stages.
  • Efficient delivery of anti-cancer agents into mitochondria is hindered by membrane barriers.
  • Targeting strategies like lipophilic cations and peptides aim to enhance mitochondrial drug delivery.

Conclusions:

  • Mitochondrial-targeted therapies offer a promising avenue for cancer treatment.
  • Overcoming mitochondrial membrane permeability is critical for drug efficacy and specificity.
  • Ongoing development of delivery strategies is essential to realize the full potential of mitochondrial targeting in oncology.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K